GLAUKOS CORP (GKOS) Stock Price, Forecast & Analysis
NYSE:GKOS • US3773221029
GKOS Key Statistics, Chart & Performance
The current stock price of GKOS is 120.27 USD. In the past month the price decreased by -4.47%. In the past year, price decreased by -4.46%.
GKOS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS turns out to be only a medium performer in the overall market: it outperformed 57.21% of all stocks.
GKOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GKOS. While GKOS seems to be doing ok healthwise, there are quite some concerns on its profitability.
GKOS Financial Highlights
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 52.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.77% | ||
| ROE | -11.39% | ||
| Debt/Equity | 0.09 |
GKOS Forecast & Estimates
22 analysts have analysed GKOS and the average price target is 135.37 USD. This implies a price increase of 12.55% is expected in the next year compared to the current price of 120.27.
For the next year, analysts expect an EPS growth of 61.44% and a revenue growth 22.62% for GKOS
GKOS Ownership
GKOS Latest News, Press Relases and Analysis
GKOS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.54 | 195.084B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.31 | 179.003B | ||
| SYK | STRYKER CORP | 25.15 | 142.513B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.29 | 112.294B | ||
| BDX | BECTON DICKINSON AND CO | 11.77 | 51.988B | ||
| IDXX | IDEXX LABORATORIES INC | 42.9 | 50.364B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.83 | 45.797B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 37.832B | ||
| RMD | RESMED INC | 21.1 | 37.336B | ||
| DXCM | DEXCOM INC | 28.94 | 28.187B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GKOS
Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Company Info
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 995
Phone: 19493679600
GLAUKOS CORP / GKOS FAQ
Can you describe the business of GLAUKOS CORP?
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
What is the current price of GKOS stock?
The current stock price of GKOS is 120.27 USD. The price increased by 2.71% in the last trading session.
Does GLAUKOS CORP pay dividends?
GKOS does not pay a dividend.
How is the ChartMill rating for GLAUKOS CORP?
GKOS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about GLAUKOS CORP (GKOS) stock?
22 analysts have analysed GKOS and the average price target is 135.37 USD. This implies a price increase of 12.55% is expected in the next year compared to the current price of 120.27.
What sector and industry does GLAUKOS CORP belong to?
GLAUKOS CORP (GKOS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the Short Interest ratio of GLAUKOS CORP (GKOS) stock?
The outstanding short interest for GLAUKOS CORP (GKOS) is 4.47% of its float.